Brief: Helix Biopharma announces deal with National Research Council of Canada
18/07/2016 21:10
July 18 (Reuters) - Helix Biopharma Corp HBP.TO
* Helix Biopharma announces agreement in principle with
National Research Council of Canada to collaborate on various
immuno-oncology initiatives
* Agreement spells out framework to enable Helix to finalize
master agreement with NRC to develop new therapeutics for cancer
immunotherapies
* Agreement allows for discussion on a potential license of
antibody previously obtained from NRC under a material transfer
agreement
Source text for Eikon: urn:newsml:reuters.com:*:nCCN4CqHzq
Further company coverage: HBP.TO
((Bengaluru Newsroom: +1-646-223-8780;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020